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Assessment of circulating CD4 count change over time in HIV-
infected subjects on antiretroviral therapy (ART) is a central compo-
nent of disease monitoring. The increasing number of HIV-infected
subjects starting therapy and the limited capacity to support CD4
count testing within resource-limited settings have fueled interest in
identifying correlates of CD4 count change such as total lympho-
cyte count, among others. The application of modeling techniques
will be essential to this endeavor due to the typically nonlinear CD4
trajectory over time and the multiple input variables necessary for
capturing CD4 variability. We propose a prediction-based classifica-
tion approach that involves first stage modeling and subsequent clas-
sification based on clinically meaningful thresholds. This approach
draws on existing analytical methods described in the receiver op-
erating characteristic curve literature while presenting an extension
for handling a continuous outcome. Application of this method to an
independent test sample results in greater than 98% positive predic-
tive value for CD4 count change. The prediction algorithm is derived
based on a cohort of n = 270 HIV-1 infected individuals from the
Royal Free Hospital, London who were followed for up to three years
from initiation of ART. A test sample comprised of n = 72 individ-
uals from Philadelphia and followed for a similar length of time is
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used for validation. Results suggest that this approach may be a use-
ful tool for prioritizing limited laboratory resources for CD4 testing
after subjects start antiretroviral therapy.
1. Introduction. Chronic HIV infection results in the progressive deple-
tion of CD4+ T lymphocytes from both lymphoid tissues and peripheral
blood. Thus, the monitoring of peripheral blood CD4 count is the stan-
dard used in decision-making concerning initiation of antiretroviral therapy
(ART), as well as monitoring response to ART over time. In 2002 and again
in 2006, the World Health Organization (WHO) proposed guidelines for ad-
ministration of ARTs in an effort to provide a clear public health approach to
utilization of these limited, yet very powerful drugs [WHO-Report (2006)].
This series of recommendations includes routine collection and monitoring
of CD4 counts to inform decisions regarding both initiation and switching
of drug regimens. However, this report also acknowledges that collection of
repeated CD4 counts may not be feasible in resource-limited settings due to
the high costs associated with such monitoring. In these instances, clinicians
are advised to initiate therapy in patients with asymptomatic HIV disease
if total lymphocyte count (TLC) falls below 1200 cells/mm3.
In this manuscript we consider modeling strategies for using alternative
surrogate markers within an acute window (3 years) post-initiation of ther-
apy. Since publication of the WHO guidelines, several reports have been
published on the clinical utility of alternative surrogate markers for moni-
toring post-therapy response and specifically the correlation between these
markers and CD4 count [Bagchi et al. (2007); Bisson et al. (2006); Fer-
ris et al. (2004); Mahajan et al. (2004); Kamya et al. (2004); Badri and
Wood (2003); Bedell et al. (2003); Spacek et al. (2003); Kumarasamy et al.
(2002)]. These investigations involve both cross-sectional and longitudinal
data and implement a variety of straightforward analytical methods. Typ-
ically, cross-sectional comparisons between CD4 count and TLC as well as
longitudinal comparisons between the change in each of these variables over
a specified time period are performed using correlation analysis [Badri and
Wood (2003); Kamya et al. (2004); Kumarasamy et al. (2002); Spacek et al.
(2003)]. A summary of analytic strategies described for these settings, and
their potential limitations, is given in the discussion; notably, the scientific
findings of these reports are variable.
In this manuscript we describe a prediction-based classification (PBC)
framework for predicting biomarker trajectories based on a binary decision
rule. PBC was originally described in the setting of classifying HIV ge-
netic variants that capture variability in a cross-sectional response to ART
[Foulkes and DeGruttola (2002, 2003)]. Within this framework, we present
two estimation procedures that both involve first stage modeling using a gen-
eralized linear mixed effect model (GLMM). In the first case, we dichotomize
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the biomarker a priori and use a logit link function. In this case, our ap-
proach reduces simply to fitting a logistic model coupled with a receiver
operator characteristic (ROC) curve analysis, which is commonly applied in
practice though it has not been described for this setting. The second esti-
mation approach we present is based on fitting a linear mixed effects model
to the observed CD4 count, as measured on a continuous scale. This later
approach may offer improved predictive performance since it incorporates
the full range of the continuous scale data. We describe both approaches
further in Section 2. Section 3 then illustrates the method through appli-
cation to two cohorts of HIV-1 infected individuals followed for three years
after initiation of ART. Some simple extensions are described in Section 4
and finally we offer a discussion of how the approaches complement existing
methods in Section 5.
2. Methods. Monitoring patient level CD4 counts over time may involve
consideration of the observed counts at a given time point, the percent
change in counts across a given period of time or some other function of pa-
tient level data. In general, interest lies in determining whether this function
of the data is above or below a threshold value. For example, in monitor-
ing absolute CD4 counts, thresholds of 200 and 350 are considered within
well-established treatment administration guidelines. A threshold of 20%,
on the other hand, is common for monitoring the percent change in CD4
between visits over time. We begin in this section by describing a general
modeling framework. We then present an approach for predicting whether
absolute CD4 is above a clinically meaningful threshold, at each of multiple
discrete time points. In Section 4 we consider extensions of this framework
that allow us to consider functions of the biomarker under study, such as
percentage change over a given time period.
2.1. Generalized linear mixed effects model. Consider the generalized lin-
ear mixed effects model (GLMM) given by
g(E[Yi]) =Xiβ +Zibi,(2.1)
where Yi = (Yi1, . . . , Yini)
T is a vector of the ni responses for individual i,
g(·) is a link function, Xi is the ni×M corresponding design matrix across
M covariates, β is the fixed-effects parameter vector and bi
i.i.d.
∼ MVN(0,D).
Here Zi is the design matrix for the random effects and will typically include
both an intercept and time component. One choice of Xi and Zi is offered in
the example of Section 3 and includes time varying values of white blood cell
count and lymphocyte percentage. This model is a natural choice for this
setting since repeated measures are taken over time on the same individual
and the time points are unevenly spaced across individuals [Fitzmaurice,
Laird and Ware (2004)].
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In this manuscript we consider two approaches to fitting the model of
equation (2.1). Since ultimately we are interested in predicting whether
CD4 count is above (or below) a given threshold, we begin by modeling
a dichotomized version of the observed CD4 data. We use the notation Y +ij
to indicate this binary representation of the observed data. That is, we de-
fine the dependent variable Y +ij = I(CD4ij > K), where CD4ij is the CD4
count at the jth time point for individual i and K is set equal to a clinically
meaningful threshold. In this case, the canonical logit link is used to model
the resulting binary outcome. Formally, if we let θij =E[Y
+
ij ] = Pr(Y
+
ij = 1),
then equation (2.1) reduces in this setting to
θij =
exp[xijβ + zijbi]
1 + exp[xijβ + zijbi]
,(2.2)
where xij and zij are the rows of Xi and Zi respectively, corresponding to
the jth measurement for individual i.
Second, we explore the utility of using the full range of the CD4 count
data by modeling CD4 as a continuous variable. That is, we let Yij =CD4ij
and g(·) be the identity function, so that the model of equation (2.1) reduces
to the linear mixed effects model (LMM), given by
Yij = xijβ + zijbi + εij ,(2.3)
where εij ∼N(0, σ
2) and bi ⊥ εij . Since we ultimately aim to predict whether
CD4 is above a given threshold, we then derive a prediction rule based on
the estimated mean and variance components from this model.
2.2. Prediction-based classification. In fitting the mixed effects model
of equation (2.1), we use the complete vector of observed data, given by
yi = (yi0, . . . , yini), for all individuals in our learning sample. In general, we
want to make predictions for new individuals under the assumption that only
baseline values of yi, given by yi0, are observed. In the usual model fitting
context, the predicted y is generated using the empirical Bayes estimates
of bi, given by b̂i = E[b|yi]. Notably, this conditions on this complete data
vector and thus is not applicable to our setting, in which only the yi0 are
available. Thus, we need to arrive at an alternative estimate of the random
effects that conditions only on the observed data for new individuals. We
consider two approaches in the context of the linear mixed model. In the
first case, we replace yi with Xiβ̂ in the formula for b̂i. This is our primary
approach, described in Section 2.2.2 and applied in the example of Section 3.
The second alternative we consider is to replace yi with the baseline measure
yi0, which is presented as an extension in Section 4.
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2.2.1. Binary outcome. After fitting the model of equation (2.1), mean
and variance parameter estimates can be used to arrive at a predicted mean
response for individual i at the jth time point. Consider first the case in
which we dichotomize CD4 count and fit the GLMM with a logit link, as
described by equation (2.2). In this case, we have the predicted probability of
CD4 count being above the threshold K at the jth time point for individual
i given by
θ̂ij =
exp[xij β̂ + zij b̂i]
1 + exp[xij β̂ + zij b̂i]
,(2.4)
where β̂ is a maximum likelihood estimate of β and b̂i = E[bi|y
+
i ] is the
conditional mean of the random effects for individual i, given the observed
data y+i . Numerical integration techniques, such as Gaussian quadrature,
are required for model fitting in this setting since no simple, closed-form
solutions to maximum likelihood estimation are available.
A simple approach to prediction in this case is to let the predicted out-
come, given by ŷij , equal 1 if θ̂ij ≥ 0.50 and 0 otherwise, where θ̂ij is defined
by equation (2.4). Alternatively, we may want to choose a prediction rule
that controls a clinically meaningful attribute. For example, in the CD4 pre-
diction setting, we may want to control the false positive rate, defined as
the proportion of individuals predicted to be above a safety threshold, when
in fact their CD4 counts are below this safe limit. In this case, we define
multiple rules, termed α-prediction rules, that are given by
ŷ+ij,α =
{
1, if θij ≥ 1−α,
0, otherwise,
(2.5)
where the unobserved θij is replaced with the estimate θ̂ij . Notably, in mak-
ing predictions for new individuals, the complete vector y+ is not available
and, thus, b̂i = E[bi|y
+
i ] in equation (2.4) cannot be calculated. In the ex-
ample provided below, we let b̂i = E[bi] = 0 for all i in our test sample. An
alternative approach for the linear model setting is described in Section 4.
Table 1
Contingency table notation for a given
α-prediction rule
y
+
ij
1 0 Total
ŷ+ij,α 1 n11 n12 n1·
0 n21 n22 n2·
Total n·1 n·2 n··
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Based on a given α-prediction rule, we can generate the contingency ta-
ble given in Table 1. Here the nkl’s are the corresponding cell counts for
k, l = 1,2. For example, n11 is the number of observations that are ob-
served to be above the threshold (y+ij = 1) and predicted to be above the
threshold (ŷ+ij,α = 1). The sensitivity of this rule is defined as the proba-
bility of correctly predicting an observation as being above the threshold
among those responses that are in fact above the threshold and is given
algebraically as Pr(ŷ+ij,α = 1|y
+
ij = 1) = n11/n·1. The corresponding speci-
ficity is given by Pr(ŷ+ij,α = 0|y
+
ij = 0) = n22/n·2 and the false positive rate
is FPα = 1− specificity = n12/n·2. Positive predictive value (PPV) and neg-
ative predictive value (NPV) are given by (n11/n1·) and (n22/n2·), respec-
tively. By varying the value of α in equation (2.5), we generate multiple
prediction rules and can construct a corresponding receiver operator char-
acteristic (ROC) curve, which offers a visual representation of the trade-off
between sensitivity and specificity. Specifically, an ROC curve is defined as a
plot of the false positive rate (x-axis) and corresponding sensitivity (y-axis)
for each of multiple classifiers, in our case prediction rules. In our setting,
each α-rule contributes one point to the ROC curve. We define the opti-
mal rule as the one that controls the FP rate at a specified level, though
alternative criterion are equally applicable.
Since the prediction rule given by equation (2.5) depends on an esti-
mate of θij that is derived based on the data, a cross-validation approach is
necessary to obtain accurate estimates of predictive performance, including
sensitivity and false positive rate. The motivation for this stems from the
need to characterize the ability to make predictions on observations that did
not contribute to the model fitting procedure. In this manuscript, we use
an independent test sample to evaluate model performance. The approach
proceeds as follows: First, model parameters are estimated using data aris-
ing from what we refer to as the learning sample. Second, the best α-rule
is identified based on the trade-off between sensitivity and specificity, again
using the learning sample data. The estimates of predictive performance
(e.g., false positive rate) based on the learning sample are referred to as
resubstitution estimates as the data used for estimating error rates are the
same as those used for deriving the prediction rule. Finally, measures of pre-
dictive performance for the chosen α-rule are reported based on applying
the rule to an independent data set, which we refer to as the test sample
data. These test sample estimates are considered unbiased reflections of pre-
dictive performance, as independent data sets are used to generate the rule
and describe its performance.
2.2.2. Continuous outcome. The prediction approach just described for
a binary outcome involves simply fitting a logistic regression model and then
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generating an ROC curve based on several probability cutoffs. While, to our
knowledge, this has not been applied to the setting of modeling biomarker
trajectories over time and specifically to CD4 monitoring, similar approaches
are used in practice in other settings [Tosteson et al. (1994); Tosteson and
Begg (1988)]. One reason that this approach may not be optimal for the
present setting is that CD4 count is measured on a continuous scale. We thus
consider a simple extension of this approach that takes into consideration
the full range of the observed CD4 count data. We begin by modeling yij =
CD4ij as a quantitative biomarker, using the linear mixed effects model of
equation (2.3), and then derive a prediction approach similar to the one
described by equation (2.5).
The model derived predicted value of yij is given by ŷ
∗
ij = xij β̂ + zij b̂i.
Here xij and zij are again respectively the rows of Xi and Zi corresponding
to the jth measurement for individual i, β̂ =
∑N
i=1(X
T
i Σ̂
−1
i Xi)
−1XTi Σ̂iyi is
the least squares estimate of β, b̂i = E(bi|yi) = D̂Z
T
i Σ̂
−1
i (yi −Xiβ̂) is the
best linear unbiased predictor (BLUP) of the random effects for individual
i, Σ̂i = V̂ar(yi) = ZiD̂Z
T
i + σ̂
2I , and D̂ and σ̂2 are the restricted maxi-
mum likelihood estimates of D and σ2, respectively. Rather than estimate
θij = Pr(CD4ij > K) of equation (2.5), we describe a one-sided prediction
interval approach to identify a rule that is similar to the one described by
this equation.
First note that the lower bound of the one-sided (1−α) prediction interval
for yij is given by
lij,α = ŷij − zα
√
Var(ŷij − yij),(2.6)
where zα is the quantile of a standard normal corresponding to a 1 − α
probability and Var(ŷij−yij) is referred to as the prediction variance. In this
manuscript, we treat this interval as an approximate credible interval, so that
we are (1−α)% certain that the random variable Yij will be greater than this
realization of the lower bound. In other words, Pr(Yij > lij,α) = (1 − α)%.
Thus, if lij,α >K, we are at least (1− α)% certain that Yij >K. In other
words, lij,α >K is equivalent to θ ≥ (1−α). As a result, the rule given by
ŷ+ij,α =
{
1, if lij,α >K,
0, otherwise,
(2.7)
is equivalent to the one given by equation (2.5). As described in McClean,
Sanders and Stroup (1991) and McCulloch and Searle (2001), the predic-
tion variance is given by Var(ŷij−xijβ−zijbi) = xij Var(β̂)x
T
ij+zij Var(̂bi−
bi)z
T
ij + xij Cov(β̂, b̂i − bi)z
T
ij where Var(β̂) =
∑N
i=1(XiΣ
−1
i X
T
i )
−1, Var(̂bi −
bi) = (
1
σ2
ZTi Zi +D
−1)−1 −Cov(β̂, b̂i − bi)X
T
i Σ
−1
i ZiD and Cov(β̂, b̂i − bi) =
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−DZTi Σ
−1
i XiVar(β̂). In our setting, we are interested in the prediction vari-
ance for a new observed value and thus have an additional σ2 term. That
is, Var(ŷij − yij) of equation (2.6) is equal to Var(ŷij − xijβ − zijbi) + σ
2.
The appropriateness of treating the above prediction interval as a credible
interval depends on prior assumptions about the parameters of our model.
Since we are using this as a means of generating a prediction rule, and not as
a tool for inference, this approximation seems reasonable. It also performs
well in the example provided in Section 3. A study of the relative advan-
tages of applying a fully Bayesian approach to approximating the posterior
predictive distribution for this data setting is ongoing research.
Again a test sample is used to characterize model performance. In the
linear mixed modeling setting, we note that Var(β̂), D̂ and σ̂ are estimated
based on the model fitting procedure that uses the learning sample data.
The remaining variance terms, Var(̂bi− bi) and Cov(β̂, b̂i− bi) as well as the
design elements xij and zij used in the calculation of lij,α of equation (2.6)
are based on the test sample data. Notably, in both modeling frameworks,
the BLUPs of the random effects can not be calculated for a new individual
for whom the response yi is not observed. One approach to handling this
unobserved data is to replace yi in the formula for b̂i with Xiβ̂ so that
b̂i = D̂Z
T
i Σ̂
−1
i (Xiβ̂ −Xiβ̂) = 0. This results in reducing ŷij to ŷij = xij β̂
and is consistent with assigning each individual the estimated population
average. In the example below, we use the prediction variance from the
usual regression setting of Var(ŷij−yij) = xij Var(β̂)x
T
ij+σ
2. This prediction
variance is less than the one described above; however, as we are varying zα
of equation (2.6) to generate a series of classification rules, the magnitude of
the interval is less relevant. An alternative approach for handling the random
effects in the linear mixed modeling framework is described in Section 4.
3. Example. The approach described in Section 2 is applied to a cohort
of N = 270 individuals from the Royal Free Hospital, London who were fol-
lowed for up to three years after initiation of ART. Detailed information on
the patient population and laboratory methods can be found in Smith et al.
(2003, 2004). The aim of our analysis is to determine the utility of baseline
CD4 count and repeated measures on WBC and lymphocyte percentage for
predicting CD4 counts over time. Our approach uses the complete CD4 count
data (across all time points) from a learning sample to generate a model;
predictions based on this model are then made, for the resubstituted data
as well as for an independent test sample, assuming that we only observe
the baseline values of CD4. Consideration is given to two clinically mean-
ingful CD4 count thresholds: K = 200 and K = 350 cells/mm3. All analyses
are performed using R version 2.7.1. The median length of follow-up is 25
months and the interquartile range (IQR) for length of follow-up is (14,32)
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months. The median number of follow-up time points is 9 with a full range
of 2 to 24. In total, there are 2635 records including baseline measurements.
The median baseline CD4 count for this cohort is 219.5 with an IQR equal
to (114,333).
Linear and generalized linear mixed effects models are fitted in R using
the lme() and lmer() functions of the nlme and lme4 packages, respectively.
We assume a piecewise linear mixed effects model for modeling CD4 count
after initiation of ART [Fitzmaurice, Laird and Ware (2004)]. This model
is appropriate since CD4 count tends to rise rapidly for approximately one
month and then proceeds to increase more gradually. Fixed effects for base-
line CD4 count (on a log base 10 scale), baseline and time varying values of
WBC and lymphocyte percentage and time before and after one month of
follow-up are included in the model as predictors. In addition, interactions
between each time component and baseline values of WBC and lymphocyte
percent are included.
The design matrix Xi for the fixed effects of equation (2.1) is thus given
by
Xi = [1N Xi1 Xi2 ],
(3.1) Xi1 =


yi0 wi0 li0 ti1 (ti1 − 1)+ wi1 li1
yi0 wi0 li0 ti2 (ti2 − 1)+ wi2 li2
...
yi0 wi0 li0 tini (tini − 1)+ wini lini

 ,
Xi2 =


ti1 ∗wi0 ti1 ∗ li0 (ti1 − 1)+ ∗wi0 (ti1 − 1)+ ∗ li0
ti2 ∗wi0 ti2 ∗ li0 (ti2 − 1)+ ∗wi0 (ti2 − 1)+ ∗ li0
...
tini ∗wi0 tini ∗ li0 (tini − 1)+ ∗wi0 (tini − 1)+ ∗ li0

 ,
where wi0 and li0 are respectively baseline WBC and baseline lymphocyte
percent, tij is time in months since initiation of ART, (tij − 1)+ is follow-up
time after the first 1 month on ART for tij > 1 and 0 otherwise, and wij and
lij are respectively WBC and lymphocyte percent at time tij . We define yi0
in Xi1 as log(CD4) for both the linear and generalized linear model although
the response variable, given by Yi = (Yi1, . . . , Yini), is dichotomized for the
generalized linear model setting. Notably, this model allows for two linear
time trends, before and after 1 month of follow-up on ART. Random person
specific intercepts and slopes before the knot are also assumed so that the
design matrix Zi for the random effects of equation (2.1) is given by
Zi =


1 ti1
1 ti2
...
1 tini

 .(3.2)
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The random effects vector in equation (2.1) is given by bTi = [ bi0 bi1 ] rep-
resenting the intercept and slope before the change point for individual i.
We begin by fitting the generalized linear model, as described in equa-
tion (2.2). In this case, post-baseline CD4 counts are dichotomized and used
as the outcome in the model fitting procedure. Predicted probabilities of
being above the CD4 threshold are estimated for each post-baseline time
point for each individual. The results of applying a probability cutoff of 0.50
are given in Table 2(a). We call this the “naive” approach since the cutoff
does not incorporate information about the resulting prediction rule. While
the sensitivities of these predictions rules (0.98 and 0.90) are high for both
thresholds, the corresponding false positive rates are also high (0.54 and
0.28). This approach thus may not be appropriate for CD4 testing since it
yields a high probability of falsely predicting that an individual’s CD4 count
is within a safe limit.
Next, several α cutoffs are considered to generate multiple prediction
rules and an ROC curve is generated, as illustrated in Figure 1(a). This is
again based on the GLMM approach to model fitting. Data corresponding to
rules with resubstitution FP rates of approximately (but not greater than)
5% and 10% and CD4 threshold cutoffs of K = 200 and 350 are provided
in Tables 2(b) and (c). Resubstitution-based summary measures are given
in Table 3(a). Based on a CD4 threshold of K = 200, a FP rate of 0.09
corresponds to a sensitivity of 0.61, a positive predictive value of 0.97 and a
negative predictive value of 0.32. For the same CD4 threshold, a FP of 0.05
corresponds to a sensitivity of 0.42, a positive predictive value of 0.98 and
a negative predictive value of 0.25.
Table 2
Observed and predicted counts (based on learning sample data)
(a) GLMM approach with a “naive” 0.50 probability cutoff
Observed
>200 <200 Total
Predicted >200 1932 215 2147
<200 34 184 218
Total 1966 399 2365
Observed
>350 <350 Total
Predicted >350 1194 289 1483
<350 137 745 882
Total 1331 1034 2365
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Table 2
Continued
(b) GLMM approach
Observed Observed
>200 <200 Total >200 <200 Total
Predicted∗ >200 826 18 844 1206 37 1243
<200 1140 381 1521 760 362 1122
Total 1966 399 2365 1966 399 2365
Observed Observed
>350 <350 Total >350 <350 Total
Predicted∗ >350 669 50 719 880 103 983
<350 662 984 1646 451 931 1382
Total 1331 1034 2365 1331 1034 2365
(c) LMM approach
Observed Observed
>200 <200 Total >200 <200 Total
Predicted∗ >200 1291 19 1319 1558 38 1596
<200 675 380 1055 408 361 769
Total 1966 399 2365 1966 399 2365
Observed Observed
>350 <350 Total >350 <350 Total
Predicted∗ >350 760 51 811 940 103 1043
<350 571 983 1554 391 931 1322
Total 1331 1034 2365 1331 1034 2365
∗Predicted counts are based on rules with resubstitution FP rate estimates of approxi-
mately (but not greater than) 5% (left panels) and 10% (right panels).
Next we fitted the linear mixed effects model, as described by equa-
tion (2.3), to the observed CD4 count data. The resulting ROC curve illus-
trating the sensitivity and corresponding false positive rates in this cohort
(resubstitution estimates) is given in Figure 1(b). Count data corresponding
to rules for which thresholds are K = 200 and 350 and the resubstitution
FP rates are approximately (but not greater than) 5% and 10% are given in
Table 2(b). Corresponding summaries, as well as 95% bootstrap confidence
intervals (CIs), are reported in Table 3(b). To arrive at CIs, we repeatedly
sample individuals with replacement and in each case, fit a linear mixed ef-
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(a)
(b)
Fig. 1. ROC curves based on resubstitution estimates. (a) GLMM, (b) LMM.
fects model. The prediction rule corresponding to FP rates of approximately
(but not greater than) 5% and 10% are selected and corresponding resubsti-
tution estimates of sensitivity, PPV and NPV are recorded. A total of 100
bootstraps are performed for each threshold and the fifth and ninety-fifth
percentiles reported.
Based on a CD4 cutoff of 200, a FP rate of 0.10 corresponds to a sensitivity
of 0.79 [95% CI (0.74, 0.83)]. In this case, the PPV is 0.98 (0.97, 0.98) and
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Table 3
Estimates of predictive performance
(a) GLMM approach
GLMM (LS) GLMM (TS)
Sens Spec PPV NPV Sens Spec PPV NPV
K = 200:
LS FP< 0.05 0.42 0.95 0.98 0.25 0.66 0.96 0.99 0.31
LS FP< 0.10 0.61 0.91 0.97 0.32 0.77 0.96 0.99 0.39
K = 350:
LS FP< 0.05 0.50 0.95 0.93 0.60 0.61 0.95 0.95 0.59
LS FP< 0.10 0.66 0.90 0.90 0.67 0.79 0.90 0.93 0.71
(b) LMM approach
LMM (LS) LMM (TS)
Sens Spec PPV NPV Sens Spec PPV NPV
K = 200:
LS FP< 0.05 0.66 0.95 0.99 0.36 0.77 0.96 0.99 0.39
(0.60, 0.75) (0.98, 0.99) (0.31, 0.46)
LS FP< 0.10 0.79 0.90 0.98 0.47 0.84 0.96 0.99 0.49
(0.74, 0.83) (0.97, 0.98) (0.37, 0.54)
K = 350:
LS FP< 0.05 0.57 0.95 0.94 0.63 0.73 0.93 0.95 0.67
(0.44, 0.67) (0.92, 0.95) (0.56, 0.70)
LS FP< 0.10 0.71 0.90 0.90 0.70 0.84 0.90 0.94 0.77
(0.65, 0.79) (0.88, 0.92) (0.66, 0.78)
the NPV is 0.47 (0.37, 0.54). This corresponds to the rule in which α =
0.035. That is, an individual’s CD4 count is predicted to be above 200 if the
probability that this measurement is greater than 200 is at least 1− 0.035 =
96.5%. For the same CD4 threshold, a FP rate of 0.05 corresponds to a
sensitivity of 0.66 (0.60, 0.75), PPV of 0.99 (0.98, 0.99) and NPV of 0.36
(0.31, 0.46).
In order to further evaluate model performance, we apply our prediction
rule to 399 observations across n= 72 individuals from an independent co-
hort in Philadelphia. We use only baseline CD4 counts to make predictions,
assuming that this is all that is available. The median baseline CD4 in this
cohort is 260.5 cells/mm3 and the IQR is (159.0,354.2). Test sample es-
timates for sensitivity, false positive rate, PPV and NPV are provided in
Tables 3(a) and (b) for each of the prediction rules. A tabular summary of
counts for one rule based on the LMM approach is given in Table 4. The
total count is n= 327 since there are 399− 72 = 327 post-baseline measure-
ments for this cohort. In this case, n= 240 measurements are predicted to
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Table 4
Observed and predicted counts (based on test sample
data)
Observed
>200 <200 Total
Predicted >200 238 2 240
<200 44 43 87
Total 282 45 327
be above the threshold, while 87 are predicted below. Since this is intended
as a prioritization tool, this rule would suggest performing a true CD4 test
on the 87 observations that are predicted below the threshold to confirm
the true value. A “savings” associated with this rule is 240/327 = 73% since
a CD4 test would not be required for this percentage of the observations.
The “cost” is the associated false positive rate of 2/45 = 4.4%. Interestingly,
the test sample estimates based on the LMM approach [Table 3(b)] appear
slightly better than the resubstitution estimates. In fact, in some cases, these
test sample estimates are greater than the 95% bootstrap confidence limits
derived based on the learning sample. This result may be a consequence of
the overall slightly higher baseline CD4 count in the Philadelphia (test sam-
ple) cohort. A discussion of the potential utility of stratified analysis (e.g.,
according to baseline CD4 counts) is provided in Section 5.
4. Extensions. In this section we briefly describe two extensions of the
method outlined in Section 2 to illustrate its flexibility and directions for
further development. First, we consider one approach to incorporating in-
formation about the individual level random effects into our prediction al-
gorithm for the linear mixed effects setting. This approach is relevant as
it provides a potential framework for incorporating observed, post-baseline
CD4 counts into the model. Additionally, it illustrates the trade-off between
using baseline data within the fixed effects design matrix, and using these
data to inform prediction of the random effects. Second, we detail how this
method can be applied to making predictions about changes in CD4 count
over time. Extensions for modeling alternative outcomes are relevant, as clin-
ical decision making generally takes into account both absolute and relative
CD4 count changes.
4.1. Using observed response data to inform BLUPs of random effects.
While leading to a prediction rule with good predictive performance, the
approach described in Section 2 does not take into account the latent effects
that result in some individuals having higher or lower responses, information
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that is typically captured in random effects. Several alternatives exist. For
example, the prediction variance used in the example above is based on the
usual regression setting, Var(ŷij − yij) = Var(xij β̂−xijβ− ε). Alternatively,
we could use Var(ŷij − yij) = Var(xij β̂ − xijβ − zijbi − ε) = xij Var(β̂)x
T
ij +
zijD̂z
T
ij + σ
2. That is, while we let b̂i = 0, we still include the true bi in the
prediction variance formula. Based on the London data, this results in slight,
yet unremarkable improvements in sensitivity (results not shown).
We can also estimate the random effects for new individuals based on
baseline data. In the example provided, we assume only baseline CD4 counts
are available, and these are used in the fixed effects design matrix rather
than informing the random effects. To begin, we propose fitting the model
of equation (2.3) with the slight modification that the observed baseline
CD4 count, given by yi0, is now included in the response vector Yi and
removed from the design matrix Xi. In order to estimate the random effects
for a new individual (whose complete response vector yi is unobserved),
we calculate the conditional expectation of the random effects, given the
baseline (observed) response yi0. That is, we replace b̂i =E(bi|yi) with b˜i =
E(bi|yi0) = (yi0 − xi0β̂0)/(D̂1,1 + σ̂
2
ε)D̂1,·, where D̂1,1 is the (1,1) element of
D̂ corresponding to the estimated variance of the intercept random effect,
D̂1,· is the column vector corresponding to the first column of D̂, β̂0 is the
first element of β̂ corresponding to the intercept fixed effect and xi0 is the
first row of Xi. This equation is derived simply by replacing the matrix
Zi with its first row and replacing the vectors yi and Xiβ̂ with their first
elements in the formula b̂i =E(bi|yi) = D̂Z
T
i Σ̂
−1
i (yi −Xiβ̂).
Notably, this is not the same prediction of bi that would have been arrived
at if the complete data vector yi were observed and so the alternative no-
tation b˜i is used. Through use of the first column of the D̂ matrix, we draw
on the estimated covariance between the random effects to fill in values for
both the intercept and slope random effects for each individual, while only
relying on baseline values of the response. Finally, we additionally replace
Var(̂bi− bi) and Cov(β̂, b̂i− bi) with Var(b˜i− bi) and Cov(β̂, b˜i− bi), respec-
tively in the formula for Var(ŷij − yij). Applications of this approach to the
London data (results not shown) are similar to those reported, suggesting
that, in this data example, using the modified BLUPs in place of treating
baseline as CD4 as a predictor variable does not improve our prediction al-
gorithm. Observed post-baseline measures of CD4 that occur prior to the
time of prediction could be incorporated similarly into the predicted random
effects.
4.2. Making predictions about the percentage change in CD4 count over
time. In Sections 2 and 3 we focus on the setting in which interests lie in
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predicting the response at a single time point. More generally, we may want
to make a prediction about a function of the CD4 counts for individual i
across a combination of time points j. For example, we may be interested
in the percentage change in CD4 count over a specified period of time,
given by the function ft(Yij) = (Yij − Yij′)/Yij where (j − j
′) = t. We can
again begin by fitting the linear model of equation (2.3) to the repeated
CD4 count measures and arriving at predictions for new observations based
on this model. The predicted percentage change for a single individual i is
then given by f̂t(yij) = (ŷij − ŷij′)/ŷij . In order to determine the prediction
variance of f̂t(yij), we use the multivariate delta method. Based on a first-
order Taylor series expansion, we have Var[f̂t(yij)] = Var[(ŷij − ŷij′)/ŷij ] =
Var[ŷij′/ŷij] ≈ U
TV U , where UT = (1/ŷij −ŷij′/ŷ
2
ij ) is the score vector
and V is the variance–covariance matrix of ( ŷij ŷij′ )
T . The matrix V is
calculated using the same formula as for Var(ŷij) above, where the vectors
xij and zij are replaced by matrices with rows corresponding to the time
points j and j′. Further exploration of the utility of fitting a LMM and
identifying an associated prediction rule for the percentage change in CD4
count, or a rule that evaluates simultaneously the absolute level and the
percentage change within the PBC framework, is ongoing research.
5. Discussion. This manuscript presents an analytic approach, which we
term PBC, for predicting a quantitative biomarker trajectory over time that
combines the generalized linear mixed effects model with an ROC curve
type approach. Two approaches to approximating the prediction rule of
equation (2.5) are considered. In the first case, we dichotomize the data a
priori and model the resulting binary outcomes over time; a generalized lin-
ear mixed effects modeling approach is applied for direct estimation of θij .
Since we ultimately aim to arrive at a binary prediction rule, this approach
is intuitively appealing and consistent with applications of the logistic model
for prediction. In the second case, we model the data using a linear mixed
effects model, a standard approach to the analysis of unevenly spaced, re-
peated measures data with a continuous response and multiple predictor
variables. The results of this model fitting procedure are used in turn to
inform predictions, in this case using a rule that involves the lower bound
of the corresponding prediction interval. This second approach also offers
intuitive appeal since it allows for use of all of the observed data to inform
the model fit. A similar approach as the one described herein can be applied
for modeling pathogenesis, though the additional population level variabil-
ity in CD4 counts in the absence of therapy may lead to lower predictive
performance.
PBC differs in two regards from methods currently employed in this set-
ting. First, we apply first-stage modeling that can incorporate the full range
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of multiple continuous and categorical predictors, as well as quantitative
data on our outcome (CD4 count) to inform our analysis. Estimated mean
and variance components from this model fitting procedure are subsequently
used to define a rule for predicting whether a function of the observed CD4
count (within and across time points) is above or below a clinically mean-
ingful threshold. Multiple patient level characteristics can be incorporated,
including observed baseline CD4 count and time-varying values of the poten-
tially predictive markers as described in Section 3. The proposed approach
is different from previously described approaches for this setting since mod-
eling is performed using all of the available data and a prediction rule is
associated with the resulting model. One potential advantage is that we are
able to draw on the full range of both the predictor and outcome data to in-
form our investigation while still providing a binary decision rule for clinical
decision making based on resulting probability estimates.
A second difference is that PBC provides a framework for modeling CD4
count trajectories over time that is not limited to characterizing changes be-
tween two time points. Specifically, we consider models with a single knot at
one month after initiation of ART to account for the rapid increase in CD4
count that is typically observed and the subsequently slower rise over time
[Laird and Ware (1982); Fitzmaurice, Laird and Ware (2004)]. The GLMM
is applied with individual level random intercept and slope terms in order
to account for the within person correlation inherent in repeated measures
data. The use of a mixed effects model for longitudinal CD4 data has been
described for monitoring response to therapy [Mahajan et al. (2004)]; how-
ever, the aim of that investigation differed in that the investigators applied
the mixed model to uncover the within and between person variability in
TLC for fixed changes in CD4 count. In our setting, the mixed model is used
as a tool within a predictive algorithm that allows for prediction across a
temporal trajectory.
Several manuscripts also report receiver operating characteristic (ROC)
curve analyses using information on TLC as well as other markers, such
as hemoglobin to predict CD4 count. To our knowledge, all such investiga-
tions involve a first-stage dichotomization of the proposed markers as well
as the outcome CD4 count. For example, Spacek et al. describe an approach
involving cutoff points for TLC (<1200 cells/mm3 and >2000 cells/mm3)
and/or hemoglobin (>12 g/dl) [Spacek et al. (2003)], while others propose
dichotomizing TLC based on whether the change over a specified time pe-
riod is greater than 0 [Badri and Wood (2003); Mahajan et al. (2004)]. CD4
count is also dichotomized (<200 cells/mm2) for each observation based
on the absolute value at a given time point or the change over a specified
period. These investigations generally include reporting of sensitivity, speci-
ficity, positive predictive value (PPV) and negative predictive value (NPV),
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where sensitivity and specificity are defined in the usual manner as the pro-
portions respectively of those predicted positive among those truly positive
and those predicted negative among those truly negative. Through consid-
eration of multiple cutoff points for both predictor and outcomes, ROC
curves are generated that illustrate the trade-off between sensitivity and
specificity.
Logistic regression models have also been described as a useful tool in
this setting [Bagchi et al. (2007); Spacek et al. (2003)]. These methods draw
strength on the continuous nature of the potentially predictive markers, such
as TLC, while using a dichotomized version of CD4 count. Logistic models
have the advantage of offering a framework for incorporating multiple con-
tinuous or categorical predictor variables and accounting for the confound-
ing and/or effect modifying role of patient specific demographic and clinical
factors. Adjusted odds ratios are reported from these model fits. While this
approach uses more information on the available data, it involves first di-
chotomizing CD4 counts and does not include reporting of sensitivity and
specificity, two clinically appealing and relevant concepts.
An extensive literature also exists on methodologies for ROC curves as
summarized in Zhou, Obuchowski and McClish (2002) and Pepe (2000b).
Within this body of research, methods for incorporating ordinal and contin-
uous predictors have been described [Pepe (1998, 2005); Tosteson and Begg
(1988)] as well as approaches to handling repeated marker data [Emir et al.
(1998)]. To our knowledge, however, these methods are developed primar-
ily for a dichotomous outcome such as “diseased” or “not diseased.” In our
setting, both the predictor variables and outcome of interest are continu-
ous biomarkers, which serve as a primary motivation for the linear mixed
effects modeling approach we describe. Specifically, we aim to incorporate
and draw strength from the complete observed response data (rather than
a dichotomized version) to arrive at a prediction rule.
Similar to our approach, methods for time-dependent ROC curves, as
described in Heagerty, Lumley and Pepe (2000), aim to characterize a time-
varying clinical measure of disease progression within a prediction frame-
work. Heagerty, Lumley and Pepe (2000) provide an eloquent approach for
the setting of a survival outcome, in which the binary indicator for disease
status is potentially censored and can vary over time, and which involves
direct modeling of the sensitivity and specificity. In our setting, the outcome
of interest is a continuous biomarker and, thus, direct modeling of the sen-
sitivity and specificity in this fashion is not tenable. Instead, we consider
two approaches, one that involves direct modeling of the probability that
the outcome is above a threshold and the second that approximates the
prediction rule through use of a corresponding prediction interval. Further
extensions involving modeling of time to CD4 count below a meaningful
threshold would be interesting.
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Methods involving generalized linear models and mixed effects models
have been described for estimating ROC curves [Albert (2007); Gatsonis
(1995); Pepe (2000a)]. As noted by Dodd and Pepe (2003), PBC in its orig-
inal formulation is an approach to estimation of the area under the ROC
curve given by the probability that the response in the group is greater than
the response is another group. The setting described herein differs, however,
since here estimation is described for the probability that an observation is
greater than a given threshold and not for the comparison of two groups. A
ROC curve is then generated based on a prediction rule that incorporates
this estimated probability. Finally, we note that our algorithm involves gen-
erating a single ROC curve based on a set of predictors determined in a
model fitting framework. This distinguishes our strategy from approaches
that aim to identify the most predictive set of markers by evaluating the
areas under the curve across several sets of predictors, such as Bisson et al.
(2008).
PBC may be a clinically useful tool for predicting whether an individual’s
CD4 count will be greater than a given threshold based on less-expensive
laboratory measures, including WBC and lymphocyte percent. For the data
example presented, using the continuous range of the CD4 data and appli-
cation of the linear mixed effects model appears to offer better predictive
performance than a first stage dichotomization and application of the gener-
alized linear mixed model. This is evidenced in both the resubstitution and
test sample estimates of predictive performance. For example, for a CD4
threshold of 350 and a test sample FP rate of 4%, the GLMM approach
results in test sample Sensitivity = 0.50, PPV = 0.78 and NPV = 0.88. The
LMM approach, on the other hand, yields test sample Sensitivity = 0.64,
PPV = 0.82 and NPV = 0.91 for the same cutoff and test sample FP rate.
While we have not demonstrated a statistically significant difference between
the two approaches, a clear trend is observed across all rules for both the
test and learning sample data.
The primary advantages of this strategy over the tools described in Sec-
tion 1 for this data setting are as follows: (1) it allows us to draw strength
from the full range of continuous outcome data (through linear modeling)
while providing us with clinically relevant measures, such as positive pre-
dictive value (through subsequent classification based on probability thresh-
olds) and (2) it allows for simultaneous consideration of unevenly spaced
biomarker measurements over time. In the example described for predict-
ing absolute CD4 count based on a 200-level threshold, a positive predic-
tive value of 0.98 is observed with a false positive rate of 0.05, suggesting
this approach may be useful in developing alternative clinical management
strategies. The relatively low NPV of 0.36 suggests that the approach de-
scribed herein may serve best as a prioritization tool that allows for the re-
duction in higher-end capacity testing, while not replacing the use of these
tests.
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The clinical utility of this tool, however, will require further consideration
of additional clinical and environmental factors as well as an in-depth anal-
ysis of a diverse array of cohorts. For example, the application presented
in Section 3 is based on data from the London cohort in which a median
baseline CD4 count of 219.5 is observed. Baseline CD4 counts at initiation of
therapy tend to be lower in resource poor settings since treatment guidelines
in these settings impose a lower threshold for starting ARTs. The implica-
tion of differing patient level characteristics such as baseline CD4 count on
the appropriateness of this approach as a diagnostic tool still requires thor-
ough assessment. Stratified analyses may also be informative in identifying
subgroups for which the tool is best suited. For example, characterizing the
relative performance among viremic and nonviremic patients, or during ear-
lier and later exposure to ARTs, will provide additional insight into the
large-scale relevance of this approach. In addition, the example presents a
prediction for each observation within an individual. Characterizing this ap-
proach for predicting that any of an array of observations for an individual
will be above the threshold would provide further insight into its utility. Fi-
nally, it may be useful to additionally incorporate the acquired CD4 counts
of those individuals who are tested because they are predicted to be below
the threshold. We are currently investigating these alternative questions and
settings.
The PBC approach we describe relies heavily on observing baseline CD4
counts. We are currently exploring application of this approach to data aris-
ing from the Women’s Interagency HIV Study (WIHS) and the Multicenter
AIDS Cohort study (MACS) cohorts in which dates of initiation of therapy
are observed only within a six month window. This presents an additional
challenge since our model includes a rapid rise in CD4 counts over the first
one month of therapy followed by a slower sustained increase. Thus, in its
current formulation, the precise time of ART initiation is crucial. Further
extensions may provide tools necessary for these alternative settings; how-
ever, collection of baseline CD4 count data at initiation of therapy for HIV
is routine in most settings and, thus, this does not diminish the potential
relevance of PBC for this application.
We also note that the proposed PBC framework is not limited to the choice
of design matrices given in Section 3. Incorporation of additional potentially
clinically relevant variables such as sex and weight in the model fitting stage
is straightforward. As the model fit improves and the prediction variance
decreases, the value of α in equation (2.5) corresponding to the best predic-
tion rule will likely change. In the extreme case that the prediction variance
tends to 0, we have that lij,α of equation (2.7) approaches ŷij regardless of
α. In this case, since the observed and predicted values would be very close,
all prediction rules would perform equally well with sensitivity and speci-
ficity close to unity. In addition, alternative more sophisticated models may
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offer improved accuracy. For example, Chu et al. (2005) describe a Bayesian
random change point model for predicting CD4 trajectories that includes
both population and individual level change points. Incorporating this mod-
eling approach into the PBC framework introduces the additional analytic
challenge of predicting individual-level change points for new patients and
is a direction of potential future development.
In summary, through combining modeling and an ROC curve approach,
PBC provides a flexible statistical framework for appropriately modeling
continuous biomarker data using all available data on the biomarker as well
as additional, potentially relevant continuous or categorical predictors. At
the same time, it offers interpretable measures of diagnostic accuracy based
on clinically determined thresholds. Notably, improved prediction of CD4
count based on less-expensive and more widely available laboratory mea-
sures, such as lymphocyte percentage and white blood cell count, may have
broad public health implications. A sound diagnostic tool could provide for
more targeted CD4 testing strategies, offering a much needed instrument in
a resource limited setting where HIV/AIDS presents the greatest burden.
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